BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 9652739)

  • 21. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.
    Jensen SS; Madsen MW; Lukas J; Binderup L; Bartek J
    Mol Endocrinol; 2001 Aug; 15(8):1370-80. PubMed ID: 11463860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction.
    Ponzio G; Loubat A; Rochet N; Turchi L; Rezzonico R; Farahi Far D; Dulic V; Rossi B
    Oncogene; 1998 Sep; 17(9):1159-66. PubMed ID: 9764826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells.
    Wang QM; Jones JB; Studzinski GP
    Cancer Res; 1996 Jan; 56(2):264-7. PubMed ID: 8542578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes.
    Ravanko K; Järvinen K; Paasinen-Sohns A; Hölttä E
    Cancer Res; 2000 Sep; 60(18):5244-53. PubMed ID: 11016654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased G1 cyclin/cdk activity in cells overexpressing the candidate oncogene, MCT-1.
    Dierov J; Prosniak M; Gallia G; Gartenhaus RB
    J Cell Biochem; 1999 Sep; 74(4):544-50. PubMed ID: 10440924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
    Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
    Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1.
    Gius DR; Ezhevsky SA; Becker-Hapak M; Nagahara H; Wei MC; Dowdy SF
    Cancer Res; 1999 Jun; 59(11):2577-80. PubMed ID: 10363976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
    Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
    J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cdk4 integrates growth stimulatory and inhibitory signals during G1 phase of hematopoietic cells.
    Ando K; Griffin JD
    Oncogene; 1995 Feb; 10(4):751-5. PubMed ID: 7862452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27.
    Park WH; Seol JG; Kim ES; Jung CW; Lee CC; Binderup L; Koeffler HP; Kim BK; Lee YY
    Exp Cell Res; 2000 Feb; 254(2):279-86. PubMed ID: 10640426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
    Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
    Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation.
    Musgrove EA; Sarcevic B; Sutherland RL
    J Cell Biochem; 1996 Mar; 60(3):363-78. PubMed ID: 8867812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1).
    Franzén A ; Heldin NE
    Biochem Biophys Res Commun; 2001 Jul; 285(3):773-81. PubMed ID: 11453659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Constitutively active K-cyclin/cdk6 kinase in Kaposi sarcoma-associated herpesvirus-infected cells.
    Van Dross R; Yao S; Asad S; Westlake G; Mays DJ; Barquero L; Duell S; Pietenpol JA; Browning PJ
    J Natl Cancer Inst; 2005 May; 97(9):656-66. PubMed ID: 15870436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overexpression of p21Cip1 or p27Kip1 in the promyelocytic leukemia cell line HL60 accelerates its lineage-specific differentiation.
    Zhou P; Yao Y; Soh JW; Weinstein IB
    Anticancer Res; 1999; 19(6B):4935-45. PubMed ID: 10697493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Srethapakdi M; Liu F; Tavorath R; Rosen N
    Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of proteasomes in T cell activation and proliferation.
    Wang X; Luo H; Chen H; Duguid W; Wu J
    J Immunol; 1998 Jan; 160(2):788-801. PubMed ID: 9551914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo.
    Ezhevsky SA; Ho A; Becker-Hapak M; Davis PK; Dowdy SF
    Mol Cell Biol; 2001 Jul; 21(14):4773-84. PubMed ID: 11416152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.